TOAST is a randomized, multi-center, placebo-controlled, double-blind clinical trial testing the efficacy and safety of a low molecular weight heparinoid (ORG 10172) in improving the outcome of patients with acute ischemic stroke. Funded by the National Institute of Neurological Diseases and Stroke (NINDS), this project has completed recruitment, enrolling 1281 patients at a total of 39 Clinical Centers. General medical, neurologic, hematologic, and radiologic data was collected on these patients using standardized case report forms over a seven-day acute treatment period and at a three month follow-up.

The CTDMC was active in the initial development and design of the TOAST trial, which included working with a separately-funded Clinical Coordinating Center, NINDS, and the TOAST Operations Committee in all phases of study design and protocol formulation. The CTDMC had primary responsibility for development of treatment allocation procedures, the data analysis plan, and the data collection and management systems. The CTDMC was responsible for performing interim reports for both an In-House Safety Committee and the NINDS Safety and Monitoring Committee. Data from TOAST are currently being analyzed by the CTDMC.